DANAHER CORP /DE/

DHR 10-K · Q4 2025
API behind this page

DHR Q4 2025 request

Playground key active
Request URL /api/financials?ticker=DHR&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 6,838 6,538 +4.6%
Show Product Lines breakouts
Nonrecurring 1,514 1,433 +5.7%
Nonrecurring · Biotechnology 350 320 +9.4%
Recurring 5,324 5,105 +4.3%
Recurring · Biotechnology 1,683 1,549 +8.7%
Show Business Segments breakouts
Biotechnology · High-growth markets 591 563 +5.0%
Biotechnology · North America 639 613 +4.2%
Biotechnology · Operating Segments 2,033 1,869 +8.8%
Biotechnology · Other developed markets 106 97 +9.3%
Biotechnology · Western Europe 697 596 +16.9%
Show Geography breakouts
High-growth markets 2,027 1,914 +5.9%
North America 2,756 2,773 -0.6%
Other developed markets 364 359 +1.4%
Western Europe 1,691 1,492 +13.3%
Show — breakouts
Revenue 23,843 23,149 +3.0%
Revenue 357 342 +4.4%
Revenue 1,765 1,714 +3.0%
Revenue 8,134 7,993 +1.8%
Revenue 4,119 4,163 -1.1%
Revenue 815 768 +6.1%
Revenue 17 -119 +114.3%
Revenue -1,714 -1,757 +2.4%
Revenue -1,589 -1,655 +4.0%
Revenue -401 -578 +30.6%
Revenue -433 -591 +26.7%
Revenue 2,813 2,694 +4.4%
Revenue 911 1,034 -11.9%
Revenue 2,720 2,637 +3.1%
Revenue 113 179 -36.9%
Cost of Revenue -2,872 -2,648 -8.5%
Gross Profit 3,966 3,890 +2.0%
Selling, General & Administrative -2,026 -2,023 -0.1%
Research & Development -438 -442 +0.9%
Operating Income 1,502 1,425 +5.4%
Show Business Segments breakouts
Biotechnology · Operating Segments 540 508 +6.3%
Show — breakouts
Operating Income 3,097 3,188 -2.9%
Operating Income 713 624 +14.3%
Operating Income -1,417 -1,122 -26.3%
Show Consolidation Items breakouts
Corporate Non Segment -87 -83 -4.8%
Other Non-Operating Income (Expense) -87 -63 -38.1%
Interest Expense -55 -61 +9.8%
Interest Income 13 14 -7.1%
Income Before Taxes 1,373 1,315 +4.4%
Income Tax Expense (Benefit) -190 -229 +17.0%
Net Income 1,197 1,086 +10.2%
Show Equity Components breakouts
Retained Earnings 1,197 1,086 +10.2%
Income Loss From Continuing Operations Per Basic Share 1.67 1.5 +11.3%
Income Loss From Continuing Operations Per Diluted Share 1.66 1.49 +11.4%
EPS (Basic) 1.69 1.5 +12.7%
EPS (Diluted) 1.68 1.49 +12.8%
Wtd Avg Shares (Basic) -1.8 -2.8 +35.7%
Wtd Avg Shares (Diluted) -1.8 -2.9 +37.9%
Comprehensive Income 1,580 -822 +292.2%
Gain Loss On Investments -99 -64 -54.7%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 4,615 2,078 +122.1%
Accounts Receivable 3,913 3,537 +10.6%
Inventory 2,489 2,330 +6.8%
Prepaid Expenses & Other Current Assets 1,739 1,552 +12.0%
Total Current Assets 12,756 9,497 +34.3%
Non-Current Assets
Property, Plant & Equipment 5,531 4,990 +10.8%
Show Geography breakouts
All other (each country individually less than 5% of total) · Reportable Geographical Components 1,424 1,251 +13.8%
DE · Reportable Geographical Components 287 251 +14.3%
GB · Reportable Geographical Components 586 519 +12.9%
SE · Reportable Geographical Components 477 384 +24.2%
US · Reportable Geographical Components 2,757 2,585 +6.7%
Other Non-Current Assets 4,209 3,990 +5.5%
Goodwill 43,151 40,497 +6.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 23,313 21,437 +8.8%
Diagnostics · Operating Segments 6,982 6,755 +3.4%
Life Sciences · Operating Segments 12,856 12,305 +4.5%
Show Range breakouts
Maximum 23.1 — —
Minimum 1.2 — —
Total Assets 83,464 77,542 +7.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 37,337 34,605 +7.9%
Diagnostics · Operating Segments 14,748 14,204 +3.8%
Life Sciences · Operating Segments 23,112 23,211 -0.4%
Show Consolidation Items breakouts
Corporate Non Segment 8,267 5,522 +49.7%
Operating Lease Right-of-Use Assets 1,214 1,084 +12.0%
Other Assets
Intangible Assets Net Excluding Goodwill 17,817 18,568 -4.0%
Current Liabilities
Debt Current 2 505 -99.6%
Accounts Payable Trade Current 1,844 1,753 +5.2%
Accrued Liabilities 4,961 4,540 +9.3%
Total Current Liabilities 6,807 6,798 +0.1%
Deferred Revenue (Current) 1,353 1,299 +4.2%
Non-Current Liabilities
Other Non-Current Liabilities 5,700 5,694 +0.1%
Long-Term Debt 18,416 15,500 +18.8%
Long-Term Debt 18,418 16,005 +15.1%
Show Debt Instrument breakouts
0.2% senior unsecured notes due 2026 · Senior Notes 1,469 1,293 +13.6%
0.3% senior unsecured notes due 2027 · Senior Notes 196 195 +0.5%
0.45% senior unsecured notes due 2028 · Senior Notes 1,466 1,291 +13.6%
0.4773% 2027 CHF Bonds · Bonds 315 — —
0.65% senior unsecured notes due 2032 · Senior Notes 339 337 +0.6%
0.75% senior unsecured notes due 2031 · Senior Notes 2,050 1,805 +13.6%
0.88755 2029 CHF Bonds · Bonds 409 — —
1.125% senior unsecured bonds due 2028 · Bonds 267 233 +14.6%
1.2% senior unsecured notes due 2027 · Senior Notes 704 620 +13.5%
1.265% 2033 CHF Bonds · Bonds 408 — —
1.35% senior unsecured notes due 2039 · Senior Notes 1,456 1,282 +13.6%
1.6249% 2037 CHF Bonds · Bonds 282 — —
1.8% senior unsecured notes due 2049 · Senior Notes 873 769 +13.5%
1.94% 2045 CHF Bonds · Bonds 157 — —
2.1% senior notes due 2026 · Senior Notes 940 828 +13.5%
2.5% senior notes due 2030 · Senior Notes 940 829 +13.4%
2.6% senior unsecured notes due 2029 · Senior Notes 798 797 +0.1%
2.6% senior unsecured notes due 2050 · Senior Notes 983 982 +0.1%
2.8% senior unsecured notes due 2051 · Senior Notes 985 985 0.0%
3.25% senior unsecured notes due 2039 · Senior Notes 892 892 0.0%
3.4% senior unsecured notes due 2049 · Senior Notes 891 890 +0.1%
4.375% senior unsecured notes due 2045 · Senior Notes 500 499 +0.2%
Euro-denominated commercial paper · Commercial Paper 933 931 +0.2%
Euro-Denominated Commercial Paper, 2026 Biopharma Euro Notes and 2026 Euro Notes 3.5 — —
Other 1 13 -92.3%
Operating Lease Liabilities 1,079 968 +11.5%
Accrued Income Taxes Noncurrent 3,013 3,138 -4.0%
Contract With Customer Liability Noncurrent 231 232 -0.4%
Stockholders' Equity
Common Stock 9 9 0.0%
Additional Paid In Capital Common Stock 17,194 16,727 +2.8%
Treasury Stock Common Value -11,353 -8,163 -39.1%
Retained Earnings 46,891 44,188 +6.1%
Accumulated Other Comprehensive Income -207 -3,218 +93.6%
Total Stockholders' Equity 52,534 49,543 +6.0%
Minority Interest 7 7 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 52,541 49,550 +6.0%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -185 -300 +38.3%
Accumulated Gain Loss Net Cash Flow Hedge Parent 217 -14 +1650.0%
Accumulated Other Comprehensive Income -207 -3,218 +93.6%
Accumulated Translation Adjustment -239 -2,904 +91.8%
Additional Paid In Capital 17,194 16,727 +2.8%
Common Stock 9 9 0.0%
Noncontrolling Interest 7 7 0.0%
Retained Earnings 46,891 44,188 +6.1%
Treasury Stock Common -11,353 -8,163 -39.1%
Total Liabilities & Equity 83,464 77,542 +7.6%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation 195 187 +4.3%
Show Business Segments breakouts
Biotechnology · Operating Segments 39 38 +2.6%
Show — breakouts
Depreciation 440 420 +4.8%
Depreciation 106 102 +3.9%
Depreciation -116 -125 +7.2%
Show Consolidation Items breakouts
Corporate Non Segment 2 3 -33.3%
Amortization Of Intangible Assets 428 408 +4.9%
Show Business Segments breakouts
Biotechnology · Operating Segments 230 213 +8.0%
Show — breakouts
Amortization Of Intangible Assets 1,553 1,486 +4.5%
Amortization Of Intangible Assets 47 47 0.0%
Amortization Of Intangible Assets 460 431 +6.7%
Stock-Based Compensation 63 57 +10.5%
Asset Impairment Charges 14 43 -67.4%
Show — breakouts
Asset Impairment Charges 130 43 +202.3%
Asset Impairment Charges -417 -179 -133.0%
Asset Impairment Charges 14 0 —
Asset Impairment Charges 0 0 —
Change in Accounts Receivable -151 -151 0.0%
Change in Inventory 184 264 -30.3%
Change in Accounts Payable 143 205 -30.2%
Change in Prepaid & Other Assets -2 -25 +92.0%
Increase Decrease In Other Accounts Payable And Accrued Liabilities 412 364 +13.2%
Net Cash from Operations 2,117 2,019 +4.9%
Investing Activities
Capital Expenditures -371 -516 +28.1%
Proceeds From Sale Of Property Plant And Equipment 23 1 +2200.0%
Payments To Acquire Investments -48 -143 +66.4%
Proceeds From Sale Maturity And Collections Of Investments 0 2 -100.0%
Other Investing Activities 12 -5 +340.0%
Net Cash from Investing -384 -694 +44.7%
Financing Activities
Payments Of Dividends -226 -195 -15.9%
Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less -33 4 -925.0%
Repayments Of Debt Maturing In More Than Three Months 0 -700 +100.0%
Share Repurchases 0 -809 +100.0%
Proceeds From Payments For Other Financing Activities -17 -11 -54.5%
Net Cash from Financing 1,322 -1,692 +178.1%
Supplemental
Income Taxes Paid -806.8 -931.7 +13.4%
Interest Paid 100 90 +11.1%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 32 -182 +117.6%
Net Change in Cash 3,087 -549 +662.3%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key